BRAF Mutant Melanoma
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations (NCT01726738) | UNC Lineberger Comprehensive Cancer Center | 2013-04-04 |
Track BRAF Mutant Melanoma automatically
Every clearance here is in the API, with alerts when new ones post.